Search Results

There are 27147 results for: content related to: A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid

  1. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study

    American Journal of Hematology

    Volume 90, Issue 4, April 2015, Pages: 314–319, María Victoria Mateos, Paul G. Richardson, Meletios A. Dimopoulos, Antonio Palumbo, Kenneth C. Anderson, Hongliang Shi, Jennifer Elliott, Edward Dow, Helgi van de Velde, Liviu Niculescu and Jesús F. San Miguel

    Article first published online : 27 FEB 2015, DOI: 10.1002/ajh.23933

  2. Effects of the proteasome inhibitor, bortezomib, on cytodifferentiation and mineralization of periodontal ligament cells

    Journal of Periodontal Research

    Volume 50, Issue 2, April 2015, Pages: 248–255, J. Kitagaki, S. Miyauchi, C. J Xie, M. Yamashita, S. Yamada, M. Kitamura and S. Murakami

    Article first published online : 20 JUN 2014, DOI: 10.1111/jre.12202

  3. You have free access to this content
    Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically

    BJU International

    Volume 109, Issue 8, April 2012, Pages: 1258–1268, Akinori Sato, Takako Asano, Keiichi Ito, Makoto Sumitomo and Tomohiko Asano

    Article first published online : 2 SEP 2011, DOI: 10.1111/j.1464-410X.2011.10533.x

  4. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage

    Molecular Carcinogenesis

    Volume 52, Issue 2, February 2013, Pages: 118–133, Daniel R. Premkumar, Esther P. Jane, Naomi R. Agostino, Joseph D. DiDomenico and Ian F. Pollack

    Article first published online : 15 NOV 2011, DOI: 10.1002/mc.21835

  5. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

    American Journal of Hematology

    Volume 90, Issue 4, April 2015, Pages: E60–E65, Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Despina Kalapanida, Constantinos Pamboucas, Elisavet Kaldara, Argyrios Ntalianis, Erasmia Psimenou, Savvas T. Toumanidis, Anna Tasidou, Evangelos Terpos and Meletios A. Dimopoulos

    Article first published online : 9 MAR 2015, DOI: 10.1002/ajh.23936

  6. You have free access to this content
    Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma

    British Journal of Haematology

    Volume 168, Issue 1, January 2015, Pages: 55–62, Michelle Furtado, Rod Johnson, Anton Kruger, Deborah Turner and Simon Rule

    Article first published online : 22 AUG 2014, DOI: 10.1111/bjh.13101

  7. Bortezomib use in a pediatric cardiac transplant center

    Pediatric Transplantation

    Volume 18, Issue 5, August 2014, Pages: 469–476, Matthew D. Zinn, Thomas J. L'Ecuyer, Omar R. Fagoaga and Sanjeev Aggarwal

    Article first published online : 14 JUN 2014, DOI: 10.1111/petr.12300

  8. You have free access to this content
    Proteasome inhibition aggravates tumor necrosis factor–mediated bone resorption in a mouse model of inflammatory arthritis

    Arthritis & Rheumatism

    Volume 63, Issue 3, March 2011, Pages: 670–680, Karin Polzer, Kirsten Neubert, Silke Meister, Benjamin Frey, Wolfgang Baum, Jörg H. Distler, Eva Gückel, Georg Schett, Reinhard E. Voll and Jochen Zwerina

    Article first published online : 25 FEB 2011, DOI: 10.1002/art.30177

  9. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines

    International Journal of Laboratory Hematology

    Volume 34, Issue 3, June 2012, Pages: 237–247, B. ZHENG, R. ZHOU, Y. GONG, X. YANG and Q. SHAN

    Article first published online : 7 DEC 2011, DOI: 10.1111/j.1751-553X.2011.01384.x

  10. You have full text access to this Open Access content
    Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition

    Cancer Science

    Volume 101, Issue 6, June 2010, Pages: 1403–1408, Daisuke Tamura, Tokuzo Arao, Kaoru Tanaka, Hiroyasu Kaneda, Kazuko Matsumoto, Kanae Kudo, Keiichi Aomatsu, Yoshihiko Fujita, Takashi Watanabe, Nagahiro Saijo, Yoshikazu Kotani, Yoshihiro Nishimura and Kazuto Nishio

    Article first published online : 15 MAR 2010, DOI: 10.1111/j.1349-7006.2010.01544.x

  11. Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy

    Glia

    Volume 58, Issue 16, December 2010, Pages: 1961–1976, Yoon Kyung Shin, So Young Jang, Hyun Kyoung Lee, Junyang Jung, Duk Joon Suh, Su-Yeong Seo and Hwan Tae Park

    Article first published online : 9 SEP 2010, DOI: 10.1002/glia.21065

  12. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer

    International Journal of Cancer

    Volume 137, Issue 3, 1 August 2015, Pages: 686–697, Sonja Thaler, Gitta Thiede, Jan G. Hengstler, Arno Schad, Marcus Schmidt and Jonathan P. Sleeman

    Article first published online : 8 JAN 2015, DOI: 10.1002/ijc.29404

  13. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer

    Journal of Surgical Oncology

    Volume 105, Issue 4, 15 March 2012, Pages: 357–364, Annette Wunderlich, Tjadina Arndt, Melina Fischer, Silvia Roth, Annette Ramaswamy, Brandon H. Greene, Cornelia Brendel, Ulrike Hinterseher, Detlef K. Bartsch and Sebastian Hoffmann

    Article first published online : 17 OCT 2011, DOI: 10.1002/jso.22113

  14. You have free access to this content
    Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib

    American Journal of Hematology

    Volume 84, Issue 10, October 2009, Pages: 657–660, Raman Sood, Harry Carloss, Robert Kerr, Jose Lopez, Martin Lee, Mark Druck, Ian B. Walters and Stephen J. Noga

    Article first published online : 30 JUL 2009, DOI: 10.1002/ajh.21517

  15. You have full text access to this Open Access content
    Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1

    Cancer Science

    Volume 100, Issue 2, February 2009, Pages: 341–348, Masaki Ri, Shinsuke Iida, Takashi Ishida, Asahi Ito, Hiroki Yano, Atsushi Inagaki, Jianmin Ding, Shigeru Kusumoto, Hirokazu Komatsu, Atae Utsunomiya and Ryuzo Ueda

    Article first published online : 5 DEC 2008, DOI: 10.1111/j.1349-7006.2008.01038.x

  16. You have free access to this content
    A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

    British Journal of Haematology

    Volume 127, Issue 2, October-II 2004, Pages: 165–172, S. Jagannath, B. Barlogie, J. Berenson, D. Siegel, D. Irwin, P. G. Richardson, R. Niesvizky, R. Alexanian, S. A. Limentani, M. Alsina, J. Adams, M. Kauffman, D.-L. Esseltine, D. P. Schenkein and K. C. Anderson

    Article first published online : 27 SEP 2004, DOI: 10.1111/j.1365-2141.2004.05188.x

  17. You have free access to this content
    Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma

    Cancer

    Volume 113, Issue 4, 15 August 2008, Pages: 765–771, John D. Hainsworth, David R. Spigel, John Barton, Cindy Farley, Marshall Schreeder, Jeremy Hon and F. Anthony Greco

    Article first published online : 9 JUN 2008, DOI: 10.1002/cncr.23606

  18. You have free access to this content
    Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction

    British Journal of Haematology

    Volume 146, Issue 3, August 2009, Pages: 270–281, Tae Young Kim, Jongmin Park, Bora Oh, Hyun Jung Min, Tae-Sook Jeong, Jae Hoon Lee, Cheolwon Suh, June-Won Cheong, Hyo Jung Kim, Sung-Soo Yoon, Seung Bum Park, Dong Soon Lee and the Korean Multiple Myeloma Working Party (KMMWP)

    Article first published online : 3 JUN 2009, DOI: 10.1111/j.1365-2141.2009.07752.x

  19. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases

    European Journal of Haematology

    Volume 80, Issue 5, May 2008, Pages: 407–418, Pavani Srimatkandada, Regina Loomis, Rocco Carbone, Srinivasan Srimatkandada and Jill Lacy

    Article first published online : 23 JAN 2008, DOI: 10.1111/j.1600-0609.2008.01044.x

  20. You have free access to this content
    A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

    British Journal of Haematology

    Volume 160, Issue 5, March 2013, Pages: 649–659, Maria T. Petrucci, Pilar Giraldo, Paolo Corradini, Adriana Teixeira, Meletios A. Dimopoulos, Igor W. Blau, Johannes Drach, Ralf Angermund, Nathalie Allietta, Esther Broer, Vivien Mitchell and Joan Bladé

    Article first published online : 7 JAN 2013, DOI: 10.1111/bjh.12198